Exai Bio and researchers at UCSF released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and smallest tumor sizes. Earlier detection of breast cancer is crucial for optimal patient outcomes but cannot always be achieved based on symptoms or mammography.
